PEOPLE - Exagen Diagnostics makes changes:
This article was originally published in Clinica
Albuquerque, New Mexico-based prognostic testing company Exagen Diagnostics has formed an advisory board to guide the development of prognostic products in the treatment of hepatitis C infection (HCV). The board consists of four physicians: Sanjeev Arora, who has been elected chairperson, Michael Fried, Robert Gish and Paul Pockros. The board will provide input on the firm's genomic marker programmes and clinical trials that impact treatment and management of hepatitis C.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.